He published on policies regarding orphan medicines and advanced therapies in Europe and internationally, on the European Clinical Trial Directive, and on the impact of biotechnology on healthcare systems.
This person wrote about policies concerning rare medicines and innovative treatments in Europe and internationally, as well as his perspectives on the European Clinical Trial Directive and how biotechnology affects healthcare systems.